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Abstract: The cardioprotective effects of adenosine and adenosine
receptor agonists have been studied extensively. However, their
therapeutic outcomes in ischemic heart disease are limited by systemic
side effects such as hypotension, bradycardia, and sedation. Equili-
brative nucleoside transporter (ENT) inhibitors may be an alternative.
By reducing the uptake of extracellular adenosine, ENT1 inhibitors
potentiate the cardioprotective effect of endogenous adenosine. They
have fewer systemic side effects because they selectively increase the
extracellular adenosine levels in ischemic tissues undergoing acceler-
ated adenosine formation. Nonetheless, long-term inhibition of ENT1
may adversely affect tissues that have low capacity for de novo
nucleotide biosynthesis. ENT1 inhibitors may also affect the cellular
transport, and hence the efﬁcacy, of anticancer and antiviral nucleoside
analogs used in chemotherapy. It has been proposed that ENT4 may
also contribute to the regulation of extracellular adenosine in the heart,
especially under the acidotic conditions associated with ischemia. Like
ENT1 inhibitors, ENT4 inhibitors should work speciﬁcally on
ischemic tissues. Theoretically, ENT4 inhibitors do not affect tissues
that rely on ENT1 for de novo nucleotide synthesis. They also have no
interaction with anticancer and antiviral nucleosides. Development of
speciﬁc ENT4 inhibitors may open a new avenue in research on
ischemic heart disease therapy.
Key Words: nucleoside transporters, adenosine, cardioprotection,
ischemia
(J Cardiovasc Pharmacol 2015;65:517–521)
INTRODUCTION
Ischemic heart disease is a major cause of heart failure and
mortality. According to the Global Atlas on Cardiovascular
Disease Prevention and Control published by the World Health
Organization in 2011, an estimated 17.3 million people died of
cardiovascular diseases in 2008, representing 30% of all global
deaths. About 40% of these deaths were due to ischemic heart
disease. Reperfusion therapies, such as percutaneous trans-
luminal coronary angioplasty, coronary stenting, and thrombo-
lytic therapy, are the ﬁrst-line treatments for ischemic heart
disease because immediate restoration of blood ﬂow to ischemic
myocardium can limit infarct size and reduce mortality. Unfor-
tunately, the reperfusion itself paradoxically induces myocardial
injury (a phenomenon known as reperfusion injury), which
attenuates the beneﬁts of myocardial reperfusion.1 In view of this,
a great deal of research has been performed to search for phar-
macological agents that can render cardiomyocytes more resistant
to the deleterious effects of ischemia–reperfusion injury.
Adenosine is an endogenous purine nucleoside that
plays a crucial role in modulating various physiological
functions in the cardiovascular system. Adenosine levels in
blood and interstitial ﬂuid increase in response to cell injury
and stress, for instance during hypoxia and ischemia. This is
because a large amount of adenosine is produced from the
breakdown of adenine nucleotides by ecto-50-nucleotidase.
The adenosine released during preconditioning by short peri-
ods of ischemia followed by reperfusion can induce cardio-
protection for subsequent sustained ischemia.2,3 This effect is
mediated through the activation of A1 and A3 adenosine re-
ceptors in cardiomyocytes and involves protein kinase C and
mitochondrial KATP channels.
4 The increased extracellular
level of adenosine also causes vasodilation, by acting through
A2 adenosine receptors on vascular smooth muscle cells, re-
sulting in increased blood ﬂow to and oxygenation of ische-
mic tissues.5 In addition to cardioprotective and vasodilatory
effects, adenosine reduces vascular smooth muscle cell pro-
liferation,6 inhibits platelet aggregation,7 and attenuates the
inﬂammatory response.8 Therefore, it has been suggested that
adenosine may slow down the vascular remodeling process
observed in hypertension and atherosclerosis.
Adenosine is currently used as an antiarrhythmic drug
for the treatment of supraventricular tachycardia. Adenosine
infusion can also reduce infarct size signiﬁcantly.9,10 However,
the therapeutic applications of adenosine in ischemic diseases
are limited by its short biological half-life, which is less than 30
seconds. This is due to the rapid uptake of extracellular
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adenosine into cells by nucleoside transporters and the sub-
sequent metabolism of adenosine into inosine and adenosine
monophosphate by adenosine deaminase and adenosine kinase,
respectively.11,12 The problem of the short half-life can be over-
come by the use of adenosine receptor agonists. However, like
adenosine, these produce systemic side effects such as hypo-
tension, renal diuresis, bradycardia, and sedation.13,14
NUCLEOSIDE TRANSPORTERS IN THE
CARDIOVASCULAR SYSTEM
There are 2 major classes of nucleoside transporter in
mammalian cells. The equilibrative nucleoside transporters
(ENTs) are facilitated diffusion systems and are sodium
independent. Four types of ENT have been characterized,
among which ENT1 and ENT2 are the most widely studied.
They are plasma membrane proteins that are broadly selective
for purine and pyrimidine nucleosides.15 They can be distin-
guished from each other by their sensitivity to inhibition by
nitrobenzylmercaptopurine riboside (NBMPR). ENT1 is in-
hibited by nanomolar concentrations of NBMPR, whereas
ENT2 is resistant to NBMPR at up to 1 mM.16 Both ENT1
and ENT2 can transport nucleobases such as hypoxanthine,
adenine, guanine, uracil, and thymine, but the efﬁciency and
apparent afﬁnity with which ENT1 transports nucleobases are
lower than those for ENT2.17–19 ENT3 is a membrane trans-
porter associated with intracellular organelles such as lyso-
somes.20 It can transport both purine and pyrimidine
nucleosides. ENT4 was ﬁrst characterized as a low-afﬁnity
high-capacity transporter for monoamines, rather than a nucle-
oside transporter.21 The ability of ENT4 to transport nucleo-
sides was conﬁrmed in 2006.22 Unlike other ENT subtypes,
ENT4 is not broadly speciﬁc for nucleosides but mainly trans-
ports adenosine. Interestingly, the activity of ENT4 is low at
neutral pH but is greatly increased at acidic pH.22
Another major class of nucleoside transporter is the
concentrative nucleoside transporters (CNTs). CNT-1 is
pyrimidine selective, CNT-2 is purine selective, and CNT-3
is broadly selective. They are sodium-dependent systems that
can transport nucleosides against a concentration gradient.23
Different nucleoside transporters are expressed in differ-
ent tissues. In general, ENTs are ubiquitous, but CNTs are
mainly found in epithelial tissues. Over 95% of adenosine
uptake by human aortic smooth muscle cells is mediated by
ENT1, and the rest is mediated by ENT2.24 Adenosine trans-
port in human umbilical vein endothelial cells is completely
dependent on ENT1.25 However, in rat microvascular endothe-
lial cells, half of the adenosine uptake is mediated by ENT1
and half by ENT2, whereas less than 1% of adenosine uptake
in these cells is attributed to CNT-2.26 Nucleoside transporters
in the heart have only been studied in rodents, not in humans.
Over 90% of the adenosine transport in isolated rat cardiomyo-
cytes was inhibited by 10 mM of NBMPR.27 Nonetheless, the
relative contributions of ENT1 and ENT2 in rat heart are still
not clearly deﬁned because 10 mM of NBMPR can completely
inhibit ENT1 and a large portion of rat ENT2 activity. In HL-1
cells, a mouse cardiomyocyte cell line, 85% of the adenosine
transport is mediated by ENT1, while 15% is mediated by
ENT2.28 In H9c2 cells, a rat cardiomyoblast, ENT2 was found
to contribute 94% of the adenosine uptake.29 The exact reason
for such an exceptionally high expression of ENT2 in H9c2
cells is unknown. However, after H9c2 cardiomyoblasts have
differentiated into cardiomyocytes, the contribution of ENT1 is
signiﬁcantly increased, indicating that the expression of differ-
ent ENTs may be cell stage–dependent.
REGULATION OF NUCLEOSIDE TRANSPORTERS
IN THE CARDIOVASCULAR SYSTEM
DURING ISCHEMIA
There are only 2 studies related to the effects of ischemia
on the expression and activities of nucleoside transporters. An
in vitro model showed that ischemia–reperfusion has no effect
on the functions of ENT1 in microvascular endothelial cells.30
However, repression of ENT1 and ENT2 transcript and
protein levels by ischemia–reperfusion was reported in
liver.31 The effects of hypoxia, which is the consequence of
ischemia, on nucleoside transporters in the cardiovascular
system are more widely reported. Hypoxia induces inhibition
of ENT1-mediated adenosine transport in human umbilical
vein endothelial cells.32 After a short period of hypoxia
(1–3 hours), a reduction in ENT1 activity results from the
activation of the p42/44 kinase–dependent pathway, but after
a long period of hypoxia (24 hours), this kinase is not
involved.32 Hypoxia-inducible factor 1 also plays a critical
role in the downregulation of nucleoside transporters in endo-
thelia.33 It is supposed that hypoxia-inducible factor 1 inter-
acts with the hypoxia-responsive element within the ENT1
promotor, thereby inhibiting expression of the gene encoding
ENT1 and causing transcriptional downregulation of
ENT1.33,34 Chronic hypoxia also downregulates ENT1
expression and activity in the cardiomyocyte cell line HL-1;
the mechanism may involve protein kinase Ce.35
Diabetic patients suffer greater morbidity from ische-
mia.36 Our previous studies have shown that ENT1 expression
and activity in cultured human aortic smooth muscle cells are
increased by .30% if the cells are incubated in high glucose
medium (which mimics the hyperglycemia of diabetes).24 The
increased expression of ENT1 involves the activation of the
mitogen-activated protein kinase–dependent pathway. Consis-
tently, ENT1-mediated adenosine transport in freshly isolated
human umbilical cord arterial smooth muscle cells from preg-
nant diabetic patients was 3-fold higher than that in normal
arterial smooth muscle cells.37 We speculate that the increased
level of ENT1 in vascular smooth muscle cells may decrease
the availability of adenosine to adenosine receptors, thereby
weakening the vasodilatory effect of adenosine during ischemia.
Diabetes-induced changes in ENT1 expression are tissue-
speciﬁc. Expression of ENT1 is decreased in endothelial cells
isolated from the umbilical veins of human diabetic subjects, in
contrast to vascular smooth muscle cells.37,38 In addition, ENT1
expression in the hearts of rats with streptozotocin-induced dia-
betes is lower than that in normal rats.39 One possible explana-
tion is that the regulation of ENT1 expression in various tissues
is controlled by different signaling pathways. The reduced
expression of ENT1 in the heart may also be a compensatory
mechanism in response to the attenuated vasodilatory effect of
adenosine in diabetes. Further experiments are required to study
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whether or not hyperglycemia per se has any direct effect on
isolated cardiomyocytes.
Hypertension is one of the major risk factors for
ischemic heart disease, and appropriate control of blood
pressure is the cornerstone of the prevention of ischemic heart
disease. So far, there has been only 1 report about the
association between hypertension and nucleoside transport-
ers. The expression of ENT1 is higher in the kidneys but
lower in the platelets of hypertensive rats.40 Although there
was no difference in ENT1 expression between the hearts of
hypertensive and normotensive rats, an age-dependent
decrease of ENT1 was observed in the hearts of hypertensive
rats.40 A preliminary study performed by the authors of this
review showed that ENT1 and ENT2 are unaffected, but the
expression of CNT-2 in the basilar arteries of hypertensive
rats is higher than that in normotensive rats.41 It will be of
interest to study whether the upregulation of CNT-2 is a pri-
mary or secondary event in the development of hypertension.
ROLES OF ENT1 IN CARDIOPROTECTION
The involvement of ENT1 in cardioprotection is
revealed by 2 ﬁndings. First, ENT1-null mice show less
myocardial infarction than wild-type littermates.42 Second,
pharmacological inhibition of ENT1 and ENT2 by NBMPR
and dipyridamole reduces the incidence of ventricular ﬁbril-
lation and attenuates regional contractile dysfunction medi-
ated by myocardial infarction due to reperfusion injury.43–46
Genetic knockout or pharmacological inhibition of ENT1 is
supposed to potentiate the effect of endogenous adenosine by
reducing and retarding the disappearance of adenosine. In
addition, inhibition of ENTs may also cause retention/trap-
ping of adenosine within cardiomyocytes, which helps replen-
ish essential adenine nucleotides (eg, ATP).47
ENT1 inhibitors should be more effective than adenosine
and adenosine receptor agonists in the treatment and prevention
of ischemic heart disease. Theoretically, ENT1 inhibitors have
fewer systemic side effects because endogenous adenosine
levels are selectively elevated in ischemic tissues undergoing
accelerated adenosine formation. However, some potential
drawbacks of ENT1 inhibitors may be underestimated. Apart
from adenosine transport, ENT1 is responsible for the cellular
uptake of other nucleosides that are critical for salvage
pathways of nucleotide biosynthesis.48,49 Therefore, inhibition
of ENT1 may adversely affect tissues that lack or have low
capacity for de novo nucleotide biosynthesis (eg, erythrocytes,
leukocytes, intestinal mucosa, and certain brain cells).50,51 In
addition, ENT1 transports anticancer and antiviral nucleoside
drugs into tumor cells and infected cells,52 and therefore the use
of ENT1 inhibitors may reduce the therapeutic effect of che-
motherapy.53–56 ENT2 inhibitors have the same problems as
ENT1 inhibitors, so they are not a suitable alternative.
INHIBITION OF ENT4: A POTENTIAL APPROACH
FOR CARDIOPROTECTION?
Unlike other ENT subtypes, which are broadly selective
for purine and pyrimidine nucleosides, ENT4 behaves more like
a monoamine transporter.21 In the brain, ENT4 serves as
a low-afﬁnity but high-capacity transporter of neurotransmitters
such as serotonin and dopamine.57 Like ENT1 and ENT2,
ENT4 is abundant in the heart, particularly in ventricular my-
ocytes and microvascular endothelial cells.22 However, the
function of ENT4 in the heart is not known. Its ability to trans-
port serotonin may be of physiological signiﬁcance because
serotonin is important in regulating cardiac development.58
Although ENT4 transports adenosine with lower efﬁciency than
monoamine substrates, it shows a much greater activity at acidic
pH, and optimal activity occurs at approximately pH 6.0.22 This
pH dependency of ENT4 may be highly relevant to tissue
ischemia because myocardial ischemia can lead to a rapid fall
in interstitial ﬂuid pH, to values as low as pH 6.6.59 No inves-
tigation has yet been attempted to test this hypothesis.
Mice with targeted deletion of the ENT4 gene have been
studied.60 ENT4-null mice are viable and fertile, with no overt
physiological abnormalities. Blood chemistry shows that serum
biomarkers in wild-type and ENT4-null mice are basically the
same. The lack of an overt phenotype in ENT4-null mice in-
dicates that ENT4 is not essential physiologically under normal
conditions. However, monoamine uptake is signiﬁcantly
reduced in the choroid plexus of ENT4-null mice. Further ex-
periments are necessary to study whether the adenosine uptake
in cardiomyocytes of ENT4-null mice is impaired or whether
the heart of ENT4-null mice is more resistant to ischemic injury.
Like ENT1 inhibitors, it is expected that ENT4 inhibitors
will prolong and amplify the effects of endogenous adenosine
generated in ischemic tissues. However, ENT4 inhibitors may
be superior to ENT1 inhibitors in 2 aspects. First, ENT4 is
speciﬁc for adenosine,21,22 so its inhibitors should have fewer
adverse effects on tissues that lack or have low capacity for de
novo nucleotide biosynthesis. Second, anticancer and antiviral
nucleoside drugs are not substrates of ENT421; they do not rely
on ENT4 for their transportation into target cells. Therefore, the
use of ENT4 inhibitors should not affect the efﬁcacy of these
nucleoside drugs. ENT4 is inhibited by decynium-22,
GBP12935, and citalopram. Unfortunately, these compounds
are not potent, not speciﬁc for ENT4, and produce unwanted
adverse reactions.61,62 Wang et al63 have recently studied a series
of dipyridamole analogs and found that an analog with a 2,6-di
(N-monohydroxyethyl) substitution on the pyrimidopyrimidine
ring can inhibit ENT4 with an IC50 of 74.4 nM, which is about
38 times more potent than dipyridamole. The selectivity of this
compound is about 80-fold and 20-fold relative to ENT1 and
ENT2, respectively. This compound may be a useful pharma-
cological tool and potential lead for ENT4-based therapeutics,
especially in ischemic heart diseases. A potential drawback of
using ENT4 inhibitors is that they may increase the levels of
catecholamine (eg, dopamine, norepinephrine, and epinephrine)
in tissues. In addition to the vasoconstrictor effects, the abun-
dance of tissue catecholamines may make monoamine oxidase–
derived hydrogen peroxide production more prominent.64 This
may have harmful effect during ischemia–reperfusion injury,
and this problem should be addressed in future research.
CONCLUSIONS
ENT4 plays a signiﬁcant role in adenosine transport in
cardiomyocytes, especially in ischemic conditions. Inhibition
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of ENT4 may be an attractive approach in the treatment of
ischemic heart disease. There are several potential advan-
tages. First, ENT4 inhibitors work speciﬁcally in ischemic
areas, so there should be few adverse systemic side effects.
Second, ENT4 inhibitors should not affect tissues that lack or
have low capacity for de novo nucleotide biosynthesis. Third,
ENT4 inhibitors should have no interaction with anticancer
and antiviral nucleoside drugs. Further studies are required to
reveal the physiological roles of ENT4 in the heart. Research
on pharmacological inhibitors of ENT4 has been started, and
hopefully a novel cardiovascular protective drug can be
developed.
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